StockData
MapLight Therapeutics, Inc. logo

MapLight Therapeutics, Inc. (MPLT) stock

MPLTNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 7/30
$6.57−0.33 (-4.78%)

Close on Nov 17, 2026Market cap $304.70MP/E –Yield –

MapLight Therapeutics r&d expenses

Research and development expenses are spending on new products and technology.

MapLight Therapeutics's R&D Expenses for the twelve months ending Jun 30, 2026 was $198.84M, up 136.3% year over year. For fiscal 2025 it was $138.35M, up 101.9% from the year before.

Annual r&d expenses

PeriodPeriod endValueChange
FY2025Dec 31, 2025$138.35M+101.9%
FY2024Dec 31, 2024$68.52M–

Quarterly r&d expenses

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$53.44M+99.0%
Q1 FY2026Mar 31, 2026$53.68M+171.3%
Q4 FY2025Dec 31, 2025$64.62M+212.0%
Q3 FY2025Sep 30, 2025$27.09M+61.1%
Q2 FY2025Jun 30, 2025$26.85M–
Q1 FY2025Mar 31, 2025$19.79M–
Q4 FY2024Dec 31, 2024$20.71M–
Q3 FY2024Sep 30, 2024$16.81M–

More MapLight Therapeutics figures

See a number that looks wrong?